Kringle Pharma Past Earnings Performance
Past criteria checks 0/6
Kringle Pharma's earnings have been declining at an average annual rate of -32.9%, while the Biotechs industry saw earnings growing at 24.8% annually. Revenues have been declining at an average rate of 82.3% per year.
Key information
-32.9%
Earnings growth rate
75.4%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -82.3% |
| Return on equity | -36.7% |
| Net Margin | -1,237.1% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Kringle Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 70 | -866 | 255 | 716 |
| 30 Sep 23 | 69 | -854 | 242 | 716 |
| 30 Jun 23 | 330 | -603 | 373 | 533 |
| 31 Mar 23 | 398 | -327 | 207 | 533 |
| 31 Dec 22 | 395 | -359 | 237 | 533 |
| 30 Sep 22 | 391 | -331 | 196 | 533 |
| 30 Jun 22 | 284 | -361 | 251 | 398 |
| 31 Mar 22 | 199 | -428 | 229 | 398 |
| 31 Dec 21 | 208 | -368 | 172 | 398 |
| 30 Sep 21 | 289 | -301 | 178 | 398 |
| 30 Jun 21 | 523 | -196 | 288 | 489 |
| 30 Sep 20 | 467 | -117 | 150 | 489 |
| 30 Sep 19 | 0 | -302 | 371 | 0 |
Quality Earnings: 4884 is currently unprofitable.
Growing Profit Margin: 4884 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4884 is unprofitable, and losses have increased over the past 5 years at a rate of 32.9% per year.
Accelerating Growth: Unable to compare 4884's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4884 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 4884 has a negative Return on Equity (-36.69%), as it is currently unprofitable.